Sugi Predict

Sugi Predict / Compounds / SCHEMBL764233

SCHEMBL764233

SCHEMBL764233

N[C@H]1CC[C@@H](C(=O)Nc2cc(-c3c[nH]c(=O)n3-c3ccc(F)cc3)ccn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 13/20 0.53
▸ GSK3B P49841 12/20 0.53
▸ MAPK10 P53779 5/20 0.48
▸ MAPK8 P45983 4/20 0.48
▸ MAPK9 P45984 1/20 0.48
▸ GSK3A P49840 3/20 0.47
▸ NR3C2 P08235 1/20 0.46
▸ PIK3C3 Q8NEB9 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL764217 0.83 MAPK14 (0.46) MAPK14GSK3BMAPK10MAPK8MAPK9
SCHEMBL13060307 0.81 MET (0.48) MAPK14GSK3BMAPK10MAPK8GSK3A
SCHEMBL10273085 0.81 MET (0.48) MAPK14GSK3BMAPK10MAPK8GSK3A
SCHEMBL765896 0.75 AXL (0.55) MAPK14GSK3BMAPK10MAPK8GSK3A
SCHEMBL13060366 0.74 MAPK14 (0.48) MAPK14MAPK10NR3C2
SCHEMBL764216 0.73 KCNH2 (0.41) MAPK14MAPK10MAPK8MAPK9NR3C2
SCHEMBL2401133 0.71 GSK3B (0.74) MAPK14GSK3BMAPK10MAPK8GSK3A
SCHEMBL2401576 0.71 GSK3B (0.74) MAPK14GSK3BMAPK10MAPK8GSK3A
SCHEMBL751261 0.71 MAPK14 (0.40) MAPK14GSK3BNR3C2
SCHEMBL11002789 0.68 ACVRL1 (0.56) GSK3BPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1439174-B1 4-IMIDAZOLIN-2-ONE COMPOUNDS AS p38 MAP KINASE INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 — — EP disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-7846933-B2 such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-12-07 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS KUBO AKIRA 2009-04-02 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed
US-7473695-B2 4-imidazolin-2-one compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088422-A1 4-IMIDAZOLIN-2-ONE COMPOUNDS OR10J3, NR4A3, NR3C2 MAPK14 2186/4885GSK3B 3230/4885MAPK10 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.